GoAI
Get started
PROCEPT BioRobotics Corporation logo

PROCEPT BioRobotics Corporation

PRCT

NASDAQHealthcareMedical - Devices

Open in GoAI

Previous close

$21.68

+$0.95 · +4.58%

Aug 21, 4:00 PM ET

PRCT company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Hold

Wait — insufficient conviction to act

Valuation

96

Deep Value

Momentum

20

Strong Down

Sentiment

69

Bullish

Risk resilience

36

High Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

PROCEPT BioRobotics Corporation specializes in pioneering surgical robotic technologies, offering innovative solutions within the field of urology. Its flagship product is the AquaBeam Robotic System, a sophisticated, image-guided surgical robot designed for minimally invasive urological procedures. This system primarily facilitates Aquablation therapy, which the company also devised, to alleviate lower urinary tract symptoms in male patients diagnosed with benign prostatic hyperplasia (BPH). As of year-end 2021, PROCEPT BioRobotics had successfully deployed 130 AquaBeam Robotic Systems across the globe, with a significant majority—78 units—located in the United States. Founded in 2007, the corporation maintains its headquarters in Redwood City, California.

Industry
Medical - Devices
Sector
Healthcare
Headquarters
US
CEO
Larry L. Wood
Listed since
Sep 15, 2021
Employees
888

Market position

Day range

Current $21.68

52-week range

Current $21.68

Open
$20.93
Previous close
$20.73
Volume
821.95K
0.52× average
Average volume
1.59M
Average daily volume
Market cap
1.23B USD
Beta
0.89
Market reference 1
50-day average
$20.6182
+5.15% above average
200-day average
$26.4994
-18.19% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
1.54B USD
P/E (TTM)
-11.18×
P/B (TTM)
3.6×
P/S (TTM)
3.66×
EV / EBITDA
-18.02×
Earnings yield
-5.47%
Free cash flow yield
-3.34%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
63.74%
Operating margin
-33.86%
Net margin
-32.54%
Return on equity
-26.12%
Return on assets
-18.81%
Return on invested capital
-23.37%

Financial health

Debt / equity
0.23×
Current ratio
6.85×

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends87%-7%-102%-197%Gross margin, FY2021: 46.02%Gross margin, FY2022: 49.44%Gross margin, FY2023: 52.17%Gross margin, FY2024: 61.07%Gross margin, FY2025: 63.70%Operating margin, FY2021: -157.12%Operating margin, FY2022: -107.61%Operating margin, FY2023: -80.16%Operating margin, FY2024: -43.04%Operating margin, FY2025: -33.71%Net margin, FY2021: -173.62%Net margin, FY2022: -116.18%Net margin, FY2023: -77.76%Net margin, FY2024: -40.72%Net margin, FY2025: -31.02%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 46.02%. Gross margin FY2022 49.44%. Gross margin FY2023 52.17%. Gross margin FY2024 61.07%. Gross margin FY2025 63.70%. Operating margin FY2021 -157.12%. Operating margin FY2022 -107.61%. Operating margin FY2023 -80.16%. Operating margin FY2024 -43.04%. Operating margin FY2025 -33.71%. Net margin FY2021 -173.62%. Net margin FY2022 -116.18%. Net margin FY2023 -77.76%. Net margin FY2024 -40.72%. Net margin FY2025 -31.02%.

Income trends

Revenue

308.05M USD+37.22%

Operating income

−103.86M USD-7.50%

Net income

−95.57M USD-4.55%
Income trends across reported periods349.78M USD182.89M USD16M USD−150.89M USDRevenue, FY2021: 34.47M USDRevenue, FY2022: 75.01M USDRevenue, FY2023: 136.19M USDRevenue, FY2024: 224.5M USDRevenue, FY2025: 308.05M USDOperating income, FY2021: −54.16M USDOperating income, FY2022: −80.72M USDOperating income, FY2023: −109.17M USDOperating income, FY2024: −96.61M USDOperating income, FY2025: −103.86M USDNet income, FY2021: −59.85M USDNet income, FY2022: −87.15M USDNet income, FY2023: −105.9M USDNet income, FY2024: −91.41M USDNet income, FY2025: −95.57M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 34.47M USD. Revenue FY2022 75.01M USD. Revenue FY2023 136.19M USD. Revenue FY2024 224.5M USD. Revenue FY2025 308.05M USD. Operating income FY2021 −54.16M USD. Operating income FY2022 −80.72M USD. Operating income FY2023 −109.17M USD. Operating income FY2024 −96.61M USD. Operating income FY2025 −103.86M USD. Net income FY2021 −59.85M USD. Net income FY2022 −87.15M USD. Net income FY2023 −105.9M USD. Net income FY2024 −91.41M USD. Net income FY2025 −95.57M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue308.05M USD224.5M USD136.19M USD75.01M USD34.47M USD
Cost of goods sold111.83M USD87.4M USD65.14M USD37.93M USD18.61M USD
Gross profit196.23M USD137.1M USD71.05M USD37.09M USD15.87M USD
Research and development71.28M USD62.3M USD48.45M USD28.98M USD18.99M USD
Selling, general, and administrative228.81M USD171.42M USD131.77M USD88.83M USD51.04M USD
Operating expenses300.09M USD233.71M USD180.22M USD117.81M USD70.03M USD
Interest income12.22M USD10.9M USD7.55M USD2.5M USD76K USD
Interest expense3.59M USD4.18M USD4M USD5.18M USD5.81M USD
Depreciation and amortization6.39M USD5.23M USD3.81M USD2.84M USD3.32M USD
Operating income−103.86M USD−96.61M USD−109.17M USD−80.72M USD−54.16M USD
Net income−95.57M USD−91.41M USD−105.9M USD−87.15M USD−59.85M USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
55%
6 beats, 5 misses, 0 met estimates
Average EPS surprise
-3.36%
11 comparable reports
Latest EPS result
-0.47
Estimate -0.46 · Miss by 1.76%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates-0.28-0.39-0.49-0.6Q1 '25MissQ2 '25BeatQ3 '25BeatQ4 '25BeatQ1 '26MissQ2 '26MissQ3 '26MissQ4 '26Estimate
Q1 2025, reported Feb 25, 2025: actual -0.35, estimate -0.34, surprise -2.94%, Miss. Q2 2025, reported Apr 24, 2025: actual -0.45, estimate -0.49, surprise +8.16%, Beat. Q3 2025, reported Aug 6, 2025: actual -0.35, estimate -0.41, surprise +14.63%, Beat. Q4 2025, reported Nov 4, 2025: actual -0.38, estimate -0.41, surprise +7.32%, Beat. Q1 2026, reported Feb 25, 2026: actual -0.53, estimate -0.32, surprise -65.63%, Miss. Q2 2026, reported Apr 29, 2026: actual -0.56, estimate -0.55, surprise -1.82%, Miss. Q3 2026, reported Aug 4, 2026: actual -0.47, estimate -0.462, surprise -1.76%, Miss. Q4 2026, reported Nov 3, 2026: actual —, estimate -0.39, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates105.1M90.54M75.97M61.4MQ1 '25MissQ2 '25BeatQ3 '25MissQ4 '25MissQ1 '26MissQ2 '26BeatQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Feb 25, 2025: actual 68.24M USD, estimate 75.98M USD, surprise -10.19%, Miss. Q2 2025, reported Apr 24, 2025: actual 69.16M USD, estimate 65.44M USD, surprise +5.69%, Beat. Q3 2025, reported Aug 6, 2025: actual 79.18M USD, estimate 84.35M USD, surprise -6.12%, Miss. Q4 2025, reported Nov 4, 2025: actual 83.33M USD, estimate 93.7M USD, surprise -11.07%, Miss. Q1 2026, reported Feb 25, 2026: actual 76.38M USD, estimate 93.77M USD, surprise -18.54%, Miss. Q2 2026, reported Apr 29, 2026: actual 83.13M USD, estimate 80.52M USD, surprise +3.24%, Beat. Q3 2026, reported Aug 4, 2026: actual 94.5M USD, estimate 92.77M USD, surprise +1.86%, Beat. Q4 2026, reported Nov 3, 2026: actual —, estimate 101.06M USD, surprise —, Comparison unavailable.

PRCT peers

Amgen Inc. logo

AMGN

Amgen Inc.

$439.33

+1.29%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.12

+1.87%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$548.05

+1.44%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$378.81

+1.16%

Sanofi logo

SNY

Sanofi

$45.85

+1.55%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$834.04

+0.90%

ETFs holding PRCT

Funds reporting this stock among their holdings, ordered by reported position size.

Vanguard Morningstar Total Stock Market ETF logoVanguard Morningstar Total Stock Market ETFVTI
Market value
31.81M
Weight
0.00%
AUM
2.3T USD
Expense ratio
0.03%
Price / 1D
$378.24+0.44%
iShares Russell 2000 ETF logoiShares Russell 2000 ETFIWM
Market value
29.77M
Weight
0.04%
AUM
81.62B USD
Expense ratio
0.19%
Price / 1D
$299.96+0.77%
Vanguard Morningstar Small-Cap ETF logoVanguard Morningstar Small-Cap ETFVB
Market value
23.07M
Weight
0.01%
AUM
183.4B USD
Expense ratio
0.03%
Price / 1D
$304.76+0.64%
Vanguard Morningstar Small-Cap Growth ETF logoVanguard Morningstar Small-Cap Growth ETFVBK
Market value
13.39M
Weight
0.03%
AUM
43.8B USD
Expense ratio
0.05%
Price / 1D
$358.65+0.70%
Vanguard Extended Market ETF logoVanguard Extended Market ETFVXF
Market value
12.28M
Weight
0.01%
AUM
93.7B USD
Expense ratio
0.05%
Price / 1D
$245.53+0.82%
iShares Russell 2000 Growth ETF logoiShares Russell 2000 Growth ETFIWO
Market value
10.75M
Weight
0.07%
AUM
15.16B USD
Expense ratio
0.24%
Price / 1D
$387.37+1.24%
Global X - Robotics & Artificial Intelligence ETF logoGlobal X - Robotics & Artificial Intelligence ETFBOTZ
Market value
9.43M
Weight
0.27%
AUM
3.43B USD
Expense ratio
0.68%
Price / 1D
$36.04+0.64%
Schwab U.S. Small-Cap ETF logoSchwab U.S. Small-Cap ETFSCHA
Market value
5.93M
Weight
0.03%
AUM
23.1B USD
Expense ratio
0.03%
Price / 1D
$34.83+0.52%

Continue in GoAI

Research PRCT

research.disclaimer